Vaxart Inc Cash Flow Conversion Efficiency
Vaxart Inc cash flow conversion efficiency. Based on the latest financial reports, Vaxart Inc (VXRT) has a cash flow conversion efficiency ratio of -0.022x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.05 Million) by net assets ($94.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vaxart Inc (1985–2025)
Cash flow conversion efficiency of Vaxart Inc from 1985 to 2025. This chart illustrates how Vaxart Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Vaxart Inc stock price today for real-time trading data and today's change.
Vaxart Inc Cash Flow Conversion Ratio Explained
Vaxart Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vaxart Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaxart Inc ranked by their cash flow conversion efficiency. Also see how much is Vaxart Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gabelli Global Small and Mid Cap Value Closed Fund
NYSE:GGZ
|
0.000x |
|
Airtel Africa Plc
LSE:AAF
|
0.286x |
|
MY EG Services Bhd
KLSE:0138
|
0.079x |
|
Meridian Holdings Inc
NASDAQ:MRDN
|
0.152x |
|
Corpovael S.A.B. de C.V
MX:CADUA
|
-0.030x |
|
Diploma PLC
LSE:DPLM
|
0.105x |
|
Mi Chang Oil
KO:003650
|
-0.025x |
|
Arrow Greentech Limited
NSE:ARROWGREEN
|
0.189x |
Annual Cash Flow Conversion Efficiency for Vaxart Inc (1985–2025)
The table below shows the annual cash flow conversion efficiency of Vaxart Inc from 1985 to 2025. Review VXRT free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $87.80 Million | $7.71 Million | 0.088x | +111.57% |
| 2024-12-31 | $58.92 Million | $-44.76 Million | -0.760x | +37.67% |
| 2023-12-31 | $57.80 Million | $-70.45 Million | -1.219x | -42.22% |
| 2022-12-31 | $110.60 Million | $-94.78 Million | -0.857x | -168.60% |
| 2021-12-31 | $187.53 Million | $-59.83 Million | -0.319x | -65.78% |
| 2020-12-31 | $123.40 Million | $-23.75 Million | -0.192x | +80.96% |
| 2019-12-31 | $12.95 Million | $-13.09 Million | -1.011x | +21.93% |
| 2018-12-31 | $11.24 Million | $-14.55 Million | -1.295x | -141.11% |
| 2017-12-31 | $18.70 Million | $-10.04 Million | -0.537x | -75.92% |
| 2016-12-31 | $46.20 Million | $-14.10 Million | -0.305x | -120.95% |
| 2015-12-31 | $69.50 Million | $-9.60 Million | -0.138x | -263.74% |
| 2014-12-31 | $86.90 Million | $-3.30 Million | -0.038x | +81.42% |
| 2013-12-31 | $68.00 Million | $-13.90 Million | -0.204x | -0.29% |
| 2012-12-31 | $68.20 Million | $-13.90 Million | -0.204x | +20.88% |
| 2011-12-31 | $58.87 Million | $-15.17 Million | -0.258x | -139.08% |
| 2010-12-31 | $60.57 Million | $39.93 Million | 0.659x | +932.93% |
| 2009-12-31 | $97.41 Million | $6.22 Million | 0.064x | +140.99% |
| 2008-12-31 | $121.38 Million | $-18.90 Million | -0.156x | +14.68% |
| 2007-12-31 | $146.53 Million | $-26.74 Million | -0.183x | +53.70% |
| 2006-12-31 | $111.39 Million | $-43.91 Million | -0.394x | +28.89% |
| 2005-12-31 | $161.83 Million | $-89.71 Million | -0.554x | -1903.87% |
| 2004-12-31 | $284.32 Million | $8.74 Million | 0.031x | +30.12% |
| 2003-12-31 | $319.32 Million | $7.54 Million | 0.024x | -59.11% |
| 2002-12-31 | $189.03 Million | $10.92 Million | 0.058x | -55.03% |
| 2001-12-31 | $187.21 Million | $24.05 Million | 0.128x | +1.35% |
| 2000-12-31 | $77.39 Million | $9.81 Million | 0.127x | -68.34% |
| 1999-12-31 | $58.20 Million | $23.30 Million | 0.400x | +19.22% |
| 1998-12-31 | $54.20 Million | $18.20 Million | 0.336x | +199.30% |
| 1997-12-31 | $75.70 Million | $-25.60 Million | -0.338x | -569.63% |
| 1996-12-31 | $86.10 Million | $6.20 Million | 0.072x | -19.40% |
| 1995-12-31 | $69.40 Million | $6.20 Million | 0.089x | +1025.53% |
| 1994-12-31 | $51.80 Million | $-500.00K | -0.010x | -105.79% |
| 1993-12-31 | $18.00 Million | $3.00 Million | 0.167x | -20.11% |
| 1992-12-31 | $13.90 Million | $2.90 Million | 0.209x | +1675.18% |
| 1991-12-31 | $15.10 Million | $-200.00K | -0.013x | -132.05% |
| 1990-12-31 | $12.10 Million | $500.00K | 0.041x | -85.68% |
| 1989-12-31 | $9.70 Million | $2.80 Million | 0.289x | +1097.94% |
| 1988-12-31 | $8.30 Million | $200.00K | 0.024x | -81.63% |
| 1986-12-31 | $6.10 Million | $800.00K | 0.131x | -64.59% |
| 1985-12-31 | $2.70 Million | $1.00 Million | 0.370x | -- |
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phas… Read more